Signs Global Deal with UEFA National Team Football as Official Accommodation and Attractions Booking Partner Signs Global Deal with UEFA National Team Football as Official Accommodation and Attractions Booking Partner

PR Newswire

AMSTERDAM, October 19, 2017 /PRNewswire/ —

Four-year contract covers 10 UEFA National Team Football competitions and over 500 matches, including UEFA EURO 2020 

Today, the global leader in connecting travellers with the widest choice of incredible places to stay, announced a new four-year exclusive global partnership with UEFA, the Union of European Football Associations, as the Official Accommodation and Attractions Booking Partner of all UEFA National Team Football Competitions from 2018 to 2022.

Reaching football fans in 55 countries, the global partnership covers 10 competitions and more than 500 matches over four years, including UEFA EURO 2020™, the European Qualifiers™ for UEFA EURO 2020 and 2022 FIFA World Cup, UEFA European Under-21 Championship 2019 and 2021, UEFA European Women’s Championships 2021 and the UEFA Nations League Finals, a new tournament debuting in 2019.

With a mission to empower people to experience the world and with over 1.4 million unique places to stay in over 120,000 destinations worldwide, including everywhere UEFA National Team Football tournament games are held, is perfectly poised to help football fans make the most of their football-inspired travels. This includes not only the most diverse range of accommodation to suit every need, but also the best ways to experience what each city has to offer.

“Nothing beats the adrenaline and excitement of watching your national team play live, whether you’re cheering them on in person in the stadium or together with your friends and family at home,” said Pepijn Rijvers, Chief Marketing Officer at “We’re thrilled to be partnering with UEFA for the next four years, as the association celebrates two things that we and our customers absolutely love-that’s football and travel. Together we can inspire more people to take a trip to see their favourite team play and enjoy one of those once-in-a-lifetime experiences for themselves.”

“We are excited to announce this ground-breaking partnership with for UEFA’s national team competitions,” said Guy-Laurent Epstein, UEFA Events SA Marketing Director. “The way that people organise their travels has drastically changed over recent years ─ and in this fast-evolving environment, has established itself as the market leader in online accommodation services, as well as one of the world’s strongest digital marketplaces.”

“For millions of football fans that will follow their team during UEFA EURO 2020, having a home away from home is an integral part of the event experience. This partnership will bring this experience to a different level, by helping fans to easily plan and organise their trips around what will be an incredible sporting and cultural event in 13 host cities across Europe,” he added.

In addition to a fully-integrated branded presence at Europe’s most prestigious international football events, including advertising, promotion and digital engagement, as UEFA’s National Team Football Official Accommodation and Attractions Booking Partner, will also be collaborating with the organisation on various campaigns and activations to amplify the partnership at key moments over the coming four years.


Established in 1996 in Amsterdam, B.V. has grown from a small Dutch start-up to one of the largest travel e-commerce companies in the world. Part of The Priceline Group (NASDAQ: PCLN), now employs more than 15,000 employees in 204 offices in 70 countries worldwide.

With a mission to empower people to experience the world, invests in digital technology that helps take the friction out of travel. At, we connect travellers with the world’s largest selection of incredible places to stay, including everything from apartments, vacation homes, and family-run B&Bs to 5-star luxury resorts, tree houses and even igloos. The website and mobile apps are available in over 43 languages, offer over 1.4 million properties, and cover more than 120,000 destinations in 228 countries and territories worldwide.

Each day, more than 1.5 million room nights are reserved on our platform. So whether travelling for business or leisure, customers can instantly book their ideal accommodation quickly and easily with, without booking fees and backed up by our promise to price match. Via our customer experience team, customers can reach 24/7 for assistance and support in 43 languages, any time of the day or night.

Follow us on Twitter and Instagram, like us on Facebook, and for the latest news, data and insights, please visit our global media room.

About UEFA: 

UEFA – the Union of European Football Associations – is the governing body of European football. It is the umbrella organisation for 55 national football associations across Europe. Amongst UEFA’s priorities are to promote the spirit of football and fair play, while also tackling all forms of discrimination and promoting inclusion, diversity and accessibility. UEFA is in regular contact with all its stakeholders involved in European football and offers support and safeguards its member associations for the overall well-being of the game.

About CAA Eleven: 

CAA Eleven is the exclusive marketing agency of UEFA appointed to manage commercial rights to UEFA national team football competitions, including the UEFA European Football Championship; the UEFA Nations League; the European Qualifiers; the UEFA European Under-21 Championship; UEFA Women’s EURO and the UEFA European Futsal Championship.

For further information, contact the Press Office:    
For sponsorship opportunities, contact:


CME Group and JPX Enter into Agreement to Launch Japanese Yen-Denominated TOPIX Futures Contract on CME

CME Group and JPX Enter into Agreement to Launch Japanese Yen-Denominated TOPIX Futures Contract on CME

PR Newswire

CHICAGO, Oct. 18, 2017 /PRNewswire/ – CME Group, the world’s leading and most diverse derivatives marketplace, and Japan Exchange Group (JPX), Asia’s leading comprehensive exchange group, today announced the launch of Japanese Yen-denominated Tokyo Stock Price Index (TOPIX) futures contracts to begin trading on CME Globex by Q1 2018, pending all relevant regulatory review periods.

This new financially-settled TOPIX futures contract will be listed with and subject to the rules and regulations of CME.  The TOPIX is a free-float adjusted market capitalization-weighted index that is calculated based on all common stocks listed on the First Section of Tokyo Stock Exchange (TSE), the cash market of JPX, and is widely used as a benchmark by institutional investors in Japan.

The launch of this TOPIX futures contract follows the license agreement which CME Group and JPX today concluded and signed.  Under the agreement, CME Group will have a worldwide exclusive license outside of Japan to the TOPIX Index for use as a reference rate in listed Japanese Yen-denominated futures and options on futures.

The addition of this TOPIX futures contract to CME Group’s existing suite of Nikkei futures including Yen- and US Dollar-denominated Nikkei 225 Index Futures, and E-mini Nikkei 225 Yen-denominated Futures, makes CME Group the only derivatives marketplace outside of Japan to offer futures contracts based on the two main Japanese indices.

CME Group has also entered into collaboration with JPX on promoting connectivity between their respective co-location facilities located in Aurora, IL and Tokyo.  Both companies will engage in marketing activities to provide awareness and availability of the telecommunication providers who offer connectivity services to customers of each Exchange’s co-location facilities.  

“Our collaboration with JPX on various initiatives has significantly strengthened our product and service offerings to better address and serve customer needs,” said Terry Duffy, Chairman and Chief Executive Officer, CME Group.  “This new TOPIX futures contract in particular, will provide a risk management tool to international investors who are looking to participate in the growth of the Japanese economy and hedging opportunities in relation to the Japanese equity markets.”

“We look forward to a fruitful relationship in growing our markets together with CME Group through a wide range of collaborative activities with CME Group and in particular, raising the awareness of TOPIX globally, and driving the use of TOPIX as a benchmark by global investors especially in North America,” said Akira Kiyota, Group CEO, JPX.  “TOPIX futures listed on Osaka Exchange (OSE), the derivatives market of JPX, is already widely used as a hedging tool by Japanese institutional investors.  With the launch of TOPIX futures on CME Globex and the promotion of connectivity services between our co-location facilities, we are confident that we will better serve the needs of international investors, helping them realize smoother and more efficient price formations on more active markets.”

CME Group also offers trading in futures and options products on various key benchmark equity indexes including Dow Jones, FTSE, NASDAQ, Russell, and Standard & Poor’s. For more information on CME Group’s Equity Index Futures products, please visit:

About CME Group                                                                                                                  

As the world’s leading and most diverse derivatives marketplace, CME Group ( is where the world comes to manage risk.  CME Group exchanges offer the widest range of global benchmark products across all major asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural products and metals.  Around the world, CME Group brings buyers and sellers together through its CME Globex® electronic trading platform and its exchanges based in Chicago, New York and London.  CME Group also operates one of the world’s leading central counterparty clearing providers through CME Clearing and CME Clearing Europe, which offer clearing and settlement services across asset classes for exchange-traded and over-the-counter derivatives.  CME Group’s products and services ensure that businesses around the world can effectively manage risk and achieve growth.

CME Group is a trademark of CME Group Inc. The Globe Logo, CME, Globex and Chicago Mercantile Exchange are trademarks of Chicago Mercantile Exchange Inc.  CBOT and the Chicago Board of Trade are trademarks of the Board of Trade of the City of Chicago, Inc.  NYMEX, New York Mercantile Exchange and ClearPort are registered trademarks of New York Mercantile Exchange, Inc.  COMEX is a trademark of Commodity Exchange, Inc.  All other trademarks are the property of their respective owners.  Further information about CME Group (NASDAQ: CME) and its products can be found at

About JPX

JPX, the Asia’s leading comprehensive exchange group, is integrated market infrastructure, with its business domain covering cash and derivatives market operation, self-regulation, and clearing Tokyo Stock Exchange (TSE), the Asia’s largest cash equities exchange, is home to more than 3,500 companies and a wide variety of ETP and REIT products, and Osaka Exchange (OSE), the derivatives arm of the group, provides trading opportunities for Japanese derivatives such as Nikkei 225 futures, TOPIX futures, and JGB futures.  In addition to efficient, stable and transparent market mechanisms, self-regulation at Japan Exchange Regulation and CCP functions provided by Japan Securities Clearing Corporation also contribute to trust and confidence in its robust and reliable market infrastructure. JPX will drive market development and continue to diversify its business portfolio as it pursues the next step forward towards becoming “Your Exchange of your Choice”. For further information, please visit our website:


View original content:


Gritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Agreement to Develop Novel RNA-Based Personalized Neoantigen Immunotherapies for Cancer Patients

VANCOUVER, British Columbia and WARMINSTER, Pa. and EMERYVILLE, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, and Gritstone Oncology, a leader in personalized cancer immunotherapies, today announced a collaboration and license agreement. Arbutus is deploying its proprietary lipid nanoparticle (LNP) technology to deliver Gritstone’s RNA-based neoantigen immunotherapy products.


Under the terms of this license agreement, Gritstone obtains worldwide access to Arbutus’ portfolio of proprietary and clinically validated LNP products and associated intellectual property. Gritstone will pay Arbutus an upfront payment, payments for achievement of development, regulatory, and commercial milestones, as well as royalties. In addition, Gritstone will reimburse Arbutus for conducting technology development and providing manufacturing and regulatory support for Gritstone’s product candidates. The license is specifically directed to the novel RNA-based platform for neoantigen immunotherapies.

“The recent phase III validation of Arbutus’ LNP platform makes them the natural partner for Gritstone as we drive our proprietary two-component immunotherapy program into the clinic in mid-2018,” said Andrew Allen, M.D., Ph.D., President and CEO of Gritstone Oncology. “Successful exploratory preclinical work with Arbutus fueled a strong bilateral desire to formalize and extend our relationship. We’re excited to continue our work with the team at Arbutus and its LNP technology as we advance our pipeline of immunotherapy product candidates.”

“This agreement again represents validation of our industry-leading LNP technology. We are excited to be working with Gritstone to advance their innovative personalized immunotherapies for the treatment of cancer,” said Dr. Mark J. Murray, Arbutus’ President and CEO. “This transaction is part of realizing the value of our LNP platform, which has broad potential to deliver nucleic acid-based products including mRNA and gene editing therapeutics, and enable Arbutus to continue to focus on development of curative therapies for HBV.”

About Arbutus Biopharma
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, please visit

About Gritstone Oncology
Gritstone Oncology is a privately-held, next-generation personalized cancer immunotherapy company. Gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors and deep financial backing to tackle fundamental challenges at the intersection of cancer genomics, immunology, and immunotherapy design. The Company’s initial goal is to leverage deep learning to identify and deploy therapeutic neoantigens from individual patients’ tumors to develop novel treatments for lung and gastric cancer. In addition to neoantigen therapy development, Gritstone is leveraging its unique antigen discovery platform to define targets for shared antigen immunotherapies, which would provide an opportunity to treat even more patients. Gritstone Oncology is headquartered in the San Francisco Bay Area with key functions located in Cambridge, MA and Pleasanton, CA. The company launched in October 2015 and has received funding from leading blue-chip biotechnology investors, including Versant Ventures, The Column Group, Clarus Funds, Frazier Healthcare Partners, RedMile, Casdin Capital, Lilly Asia Ventures, Trinitas Capital, GV, and Alexandria Venture Investments. More information can be found at or @gritstoneonc.

Forward-Looking Statements and Information
This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements in this press release include statements about deploying Arbutus’ proprietary lipid nanoparticle (LNP) technology to deliver Gritstone’s RNA-based neoantigen immunotherapy products; Gritstone paying Arbutus an upfront payment, payments for achievement of development, regulatory, and commercial milestones, as well as royalties; Gritstone reimbursing Arbutus for conducting technology development and providing manufacturing and regulatory support for Gritstone’s product candidates; the potential of Arbutus’ LNP platform to deliver nucleic acid-based products including mRNA and gene editing therapeutics; and discovering, developing and commercializing a cure for chronic hepatitis B virus (HBV) infection. 

With respect to the forward-looking statements contained in this press release, Arbutus has made numerous assumptions regarding, among other things: the successful implementation of the collaboration and license agreement; the continued demand for Arbutus’ assets, including its LNP technology; and the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause Arbutus’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: the collaboration and license agreement may not be implemented to the extent expected, if at all; demand for Arbutus’ assets may lower; economic and market conditions may worsen; and market shifts may require a change in strategic focus.

A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus’ Annual Report on Form 10-K and Arbutus’ continuous disclosure filings, which are available at and at All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

Contact Information – Arbutus

Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604-419-3200

Tiffany Tolmie
Manager, Investor Relations
Phone: 604-419-3200

David Schull
Russo Partners
Phone: 858-717-2310

Contact Information – Gritstone

Dan Budwick
Phone: 973-271-6085

Primary Logo